| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Ubenimex | NK-421; NSC-265489; 1580RB | Approved | Nippon Kayaku, Eiger BioPharmaceuticals | Ubenimex Tablets | cfda | Acute myeloid Leukemia (AML), Cancer chemotherapy | 2014-11-17 | Lymphoblastic leukaemia | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| JNJ-40929837 | JNJ-40929837 | Phase Ⅱ | Johnson & Johnson | Asthma | Details |
| BI-691751 | BI-691751 | Phase Ⅰ | Boehringer Ingelheim | Atherosclerosis | Details |
| DG-051 | DG-051,DG051 | Phase Ⅱ | Amgen | Myocardial infarction (MI) | Details |
| JNJ-27265732 | Preclinical | Johnson & Johnson | Atopic dermatitis, Inflammatory bowel disease, Asthma | Details | |
| Acebilustat | CTX-4430; EP-501 | Phase Ⅱ | Celtaxsys | Cystic fibrosis (CF) | Details |
This web search service is supported by Google Inc.
A-Z